Pfizer to Acquire Array Biopharma for ~$11.4B
Shots: Pfizer to acquire Array Biopharma in all-stock transaction for $48/share making the total deal value ~11.4B, with its expected completion in H2’19
[Read More...]
Array Biopharma
Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer
Shots: The P-III BEACON CRC study results involves assessing of Braftovi (encorafenib) + Erbitux (cetuximab), with/without Mektovi (binimetinib) vs Erbitux and irinotecan-based therapy
[Read More...]
Array Biopharma Reports Results of Triplet Combination Therapy in P-III BEACON CRC Trial for BRAF-Mutant Metastatic Colorectal Cancer (mCRC)
Shots: The safety lead-in P-III BEACON CRC study involves assessing of a triplet combination Braftovi (encorafenib), Mektovi (binimetinib) & Erbitux (cetuximab) in patients
[Read More...]